{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:13:27Z","timestamp":1777907607973,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00210-017-1377-0","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T09:08:45Z","timestamp":1492679325000},"page":"769-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inhibition of the CRF1 receptor influences the activity of antidepressant drugs in the forced swim test in rats"],"prefix":"10.1007","volume":"390","author":[{"given":"Andrzej","family":"Wr\u00f3bel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-8950","authenticated-orcid":false,"given":"Anna","family":"Serefko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Szopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol","family":"Rojek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Poleszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Skalicka-Wo\u017aniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"Dudka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,20]]},"reference":[{"key":"1377_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.0.1600001","volume":"160","author":"L Arborelius","year":"1999","unstructured":"Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1\u201312","journal-title":"J Endocrinol"},{"key":"1377_CR2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbr.2014.05.035","volume":"270","author":"CH Bourke","year":"2014","unstructured":"Bourke CH, Glasper ER, Neigh GN (2014) SSRI or CRF antagonism partially ameliorate depressive-like behavior after adolescent social defeat. Behav Brain Res 270:295\u2013299","journal-title":"Behav Brain Res"},{"key":"1377_CR3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2003.11.032","volume":"485","author":"S Chaki","year":"2004","unstructured":"Chaki S, Nakazato A, Kennis L, Nakamura M, Mackie C, Sugiura M, Vinken P, Ashton D, Langlois X, Steckler T (2004) Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995\/CRA0450. Eur J Pharmacol 485:145\u2013158","journal-title":"Eur J Pharmacol"},{"key":"1377_CR4","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1523\/JNEUROSCI.06-10-02908.1986","volume":"6","author":"PB Chappell","year":"1986","unstructured":"Chappell PB, Smith MA, Kilts CD, Bissette G, Ritchie J, Anderson C, Nemeroff CB (1986) Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci 6:2908\u20132914","journal-title":"J Neurosci"},{"key":"1377_CR5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1176\/ajp.150.4.656","volume":"150","author":"MD De Bellis","year":"1993","unstructured":"De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA (1993) Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 150:656\u2013657","journal-title":"Am J Psychiatry"},{"key":"1377_CR6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0304-3940(95)11612-Z","volume":"192","author":"P Fadda","year":"1995","unstructured":"Fadda P, Pani L, Porcella A, Fratta W (1995) Chronic imipramine, L-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain. Neurosci Lett 192:121\u2013123","journal-title":"Neurosci Lett"},{"key":"1377_CR7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0006-3223(01)01273-2","volume":"51","author":"R Galard","year":"2002","unstructured":"Galard R, Catalan R, Castellanos JM, Gallart JM (2002) Plasma corticotropin-releasing factor in depressed patients before and after the dexamethasone suppression test. Biol Psychiatry 51:463\u2013468","journal-title":"Biol Psychiatry"},{"key":"1377_CR8","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1021\/jm990590f","volume":"43","author":"PJ Gilligan","year":"2000","unstructured":"Gilligan PJ, Robertson DW, Zaczek R (2000) Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J Med Chem 43:1641\u20131660","journal-title":"J Med Chem"},{"key":"1377_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1124\/jpet.301.1.333","volume":"301","author":"G Griebel","year":"2002","unstructured":"Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrie P (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylp henyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333\u2013345","journal-title":"J Pharmacol Exp Ther"},{"key":"1377_CR10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1124\/jpet.103.052092","volume":"311","author":"SC Heinrichs","year":"2004","unstructured":"Heinrichs SC, Koob GF (2004) Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J Pharmacol Exp Ther 311:427\u2013440","journal-title":"J Pharmacol Exp Ther"},{"key":"1377_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1520-6394(1998)8:2<71::AID-DA5>3.0.CO;2-N","volume":"8","author":"I Heuser","year":"1998","unstructured":"Heuser I, Bissette G, Dettling M, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Nemeroff CB, Holsboer F (1998) Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress Anxiety 8:71\u201379","journal-title":"Depress Anxiety"},{"key":"1377_CR12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejphar.2007.12.032","volume":"583","author":"F Holsboer","year":"2008","unstructured":"Holsboer F, Ising M (2008) Central CRH system in depression and anxiety\u2014evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583:350\u2013357","journal-title":"Eur J Pharmacol"},{"key":"1377_CR13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0196-9781(89)90167-8","volume":"10","author":"P Joanny","year":"1989","unstructured":"Joanny P, Steinberg J, Zamora AJ, Conte-Devolx B, Millet Y, Oliver C (1989) Corticotropin-releasing factor release from in vitro superfused and incubated rat hypothalamus. Effect of potassium, norepinephrine, and dopamine. Peptides 10:903\u2013911","journal-title":"Peptides"},{"key":"1377_CR14","first-page":"15","volume":"453","author":"B Lee","year":"2009","unstructured":"Lee B, Shim I, Lee HJ, Yang Y, Hahm DH (2009) Effects of acupuncture on chronic corticosterone-induced depression-like behavior and expression of neuropeptide Y in the rats. Neurosci Lett 453:15\u201316","journal-title":"Neurosci Lett"},{"key":"1377_CR15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-2999(97)00025-3","volume":"323","author":"RS Mansbach","year":"1997","unstructured":"Mansbach RS, Brooks EN, Chen YL (1997) Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 323:21\u201326","journal-title":"Eur J Pharmacol"},{"key":"1377_CR16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archpsyc.1988.01800300075009","volume":"45","author":"CB Nemeroff","year":"1988","unstructured":"Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M (1988) Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45:577\u2013579","journal-title":"Arch Gen Psychiatry"},{"key":"1377_CR17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejphar.2004.04.010","volume":"492","author":"DH Overstreet","year":"2004","unstructured":"Overstreet DH, Keeney A, Hogg S (2004) Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. Eur J Pharmacol 492:195\u2013201","journal-title":"Eur J Pharmacol"},{"key":"1377_CR18","unstructured":"Paxinos, G., Watson, C (2008) The Rat Brain in Stereotaxic Coordinates. Compact Sixth Edition, Elsevier"},{"key":"1377_CR19","first-page":"327","volume":"229","author":"RD Porsolt","year":"1977","unstructured":"Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327\u2013336","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"1377_CR20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327\u2013336","journal-title":"World J Urol"},{"key":"1377_CR21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0006-8993(01)02405-2","volume":"902","author":"LK Takahashi","year":"2001","unstructured":"Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP (2001) Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902:135\u2013142","journal-title":"Brain Res"},{"key":"1377_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-1781(93)90002-X","volume":"46","author":"RC Veith","year":"1993","unstructured":"Veith RC, Lewis N, Langohr JI, Murburg MM, Ashleigh EA, Castillo S, Peskind ER, Pascualy M, Bissette G, Nemeroff CB (1993) Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res 46:1\u20138","journal-title":"Psychiatry Res"},{"key":"1377_CR23","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00192-016-3027-3","volume":"27","author":"A Wrobel","year":"2016","unstructured":"Wrobel A, Serefko A, Poleszak E, Rechberger T (2016) Fourteen-day administration of corticosterone may induce detrusor overactivity symptoms. Int Urogynecol J 27:1713\u20131721","journal-title":"Int Urogynecol J"},{"key":"1377_CR24","first-page":"181","volume":"292","author":"M Yamano","year":"2000","unstructured":"Yamano M, Yuki H, Yasuda S, Miyata K (2000) Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J Pharmacol Exp Ther 292:181\u2013187","journal-title":"J Pharmacol Exp Ther"},{"key":"1377_CR25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1124\/jpet.102.046128","volume":"305","author":"G Zhang","year":"2003","unstructured":"Zhang G, Huang N, Li YW, Qi X, Marshall AP, Yan XX, Hill G, Rominger C, Prakash SR, Bakthavatchalam R, Rominger DH, Gilligan PJ, Zaczek R (2003) Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+\/\u2212)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors. J Pharmacol Exp Ther 305:57\u201369","journal-title":"J Pharmacol Exp Ther"},{"key":"1377_CR26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-3956(00)00016-9","volume":"34","author":"AW Zobel","year":"2000","unstructured":"Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171\u2013181","journal-title":"J Psychiatr Res"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-017-1377-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-017-1377-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-017-1377-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T23:09:52Z","timestamp":1601939392000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-017-1377-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1007\/s00210-017-1377-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,20]]}}}